SCHEMBL9926006

SCHEMBL9926006

COc1ccc(S(=O)(=O)N2C[C@@H](C(=O)N3CCN(c4cc(OC)ccc4OC)CC3)[C@H](c3ccccc3)C2)cc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.58
MEN1 O00255 1/20 0.58
POLB P06746 2/20 0.52
TP53 P04637 1/20 0.52
ALDH1A1 P00352 5/20 0.49
HTT P42858 3/20 0.49
LMNA P02545 2/20 0.49
GAA P10253 2/20 0.49
MC4R P32245 1/20 0.48
KDM4E B2RXH2 1/20 0.48
PKM P14618 2/20 0.47
TSHR P16473 1/20 0.46
MAPT P10636 2/20 0.45
RECQL P46063 1/20 0.45
GFER P55789 1/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13987582 0.93 KMT2A (0.50) KMT2AMEN1POLBTP53ALDH1A1
SCHEMBL9926010 0.91 KMT2A (0.48) KMT2AMEN1POLBTP53ALDH1A1
SCHEMBL9926129 0.90 MEN1 (0.47) KMT2AMEN1POLBALDH1A1HTT
SCHEMBL9926004 0.88 MC4R (0.52) KMT2AMEN1ALDH1A1HTTLMNA
SCHEMBL9926057 0.88 SMN1; SMN2 (0.52) KMT2AMEN1POLBALDH1A1HTT
SCHEMBL13987580 0.85 MEN1 (0.51) KMT2AMEN1POLBTP53ALDH1A1
SCHEMBL9926096 0.85 MC4R (0.47) KMT2AMEN1ALDH1A1HTTLMNA
SCHEMBL9926007 0.85 POLB (0.52) KMT2AMEN1POLBTP53ALDH1A1
SCHEMBL9926042 0.83 POLB (0.56) KMT2AMEN1POLBALDH1A1HTT
SCHEMBL13987584 0.83 THRB (0.56) KMT2AMEN1ALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836180-B1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI SA (FR) 2012-06-13 EP disclosed
US-7468369-B2 Sulfonyl pyrrolidines, method for producing the same and their use as drugs SANOFI-AVENTIS (FR) 2008-12-23 US disclosed
US-7468369-B2 Sulfonyl pyrrolidines, method for producing the same and their use as drugs SANOFI-AVENTIS (FR) 2008-12-23 US disclosed
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-21 US disclosed
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SLC5A1, SLC5A2, KCNJ1 KMT2A 4211/4885MEN1 1475/4885POLB 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.